PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00877539
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Manchester, United Kingdom
A Study of Tanezumab in Adults With Chronic Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- Biological: Tanezumab 20 mg IVBiological: Tanezumab 10 mg IVBiological: Tanezumab 5 mg IVBiological: Placebo for tanezumab
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1359
- Registration Number
- NCT00876187
- Locations
- ๐บ๐ธ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
๐บ๐ธPinnacle Research Group LLC, Anniston, Alabama, United States
๐บ๐ธSimon Williamson Clinic, PC, Birmingham, Alabama, United States
A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PF-00868554 or Placebo
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2009-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00875628
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Glendale, California, United States
A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoonยฎ Tablets (Guilin-China) In Healthy Subjects
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00875030
- Locations
- ๐ฎ๐ณ
Pfizer Investigational Site, Navi Mumbai, Maharashtra, India
Study In Patients With Kidney Cancer Treated With Sutent
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT00873210
- Locations
- ๐ธ๐ฐ
Pfizer Investigational Site, Zilina, Slovakia
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00871494
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Okayama-city, Japan
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: Inotuzumab Ozogamicin (CMC-544)
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT00868608
- Locations
- ๐บ๐ธ
University of Alabama Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT00868530
- Locations
- ๐จ๐ณ
Pfizer Investigational Site, Shanghai, China
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- Drug: inotuzumab ozogamicin (CMC-544)
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00867087
- Locations
- ๐บ๐ธ
Loyola University Medical Center, Foster G. McGraw Hospital and Satellites, Maywood, Illinois, United States
๐บ๐ธTufts Medical Center, Boston, Massachusetts, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers
- Conditions
- Pharmacokinetics
- Interventions
- Drug: Treatment ADrug: Treatment B
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00867282
- Locations
- ๐ธ๐ฌ
Pfizer Investigational Site, Singapore, Singapore